The diagnosis of rheumatoid arthritis (RA) is primarily based on clinical symptoms, so it is
often difficult to diagnose RA in very early stages of the disease. A disease-specific …

Objective Since modern treatment of rheumatoid arthritis (RA) is shifting toward aggressive
antirheumatic therapy in an early phase of the disease, diagnostic tests with high specificity …

Objective To study the predictive value of anti–cyclic citrullinated peptide antibody (anti‐
CCP) in patients with recent‐onset rheumatoid arthritis (RA). Methods Outcome in terms of …

Background Anti–tumour necrosis factor (TNF) agents are effective in treating people with
rheumatoid arthritis (RA), but are associated with (dose‐dependent) adverse effects and …

Objective To systematically review studies addressing prediction of successful dose
reduction or discontinuation of a biologic agent in rheumatoid arthritis (RA). Methods …

Background: Tumour necrosis factor α (TNFα) neutralising antibody constructs are
increasingly being used to treat rheumatoid arthritis (RA). Objective: To determine potential …

Identifying mutations that cause specific osteochondrodysplasias will provide novel insights
into the function of genes that are essential for skeletal morphogenesis. We report here that …

OBJECTIVE: To identify risk factors for surgical site infection (SSI) in patients with
rheumatoid arthritis (RA) with special attention for anti-tumor necrosis factor (anti-TNF) …

Objective: Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity
and a reduced life expectancy, especially in patients with rapidly progressive diffuse …

Objective To evaluate whether a disease activity guided strategy of dose reduction of two
tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in …